Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.63 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563387 | 0.89 | CDK1 (0.64) | CDK1CCNB1CA2CA9L3MBTL1 | |
| Sucrose SCHEMBL8909548 | 0.87 | CDK1 (0.64) | CDK1CCNB1CA2CA9L3MBTL1 | |
| Sucrose SCHEMBL2905150 | 0.87 | CDK1 (0.80) | CDK1CCNB1CA2CA9L3MBTL1 | |
| SCHEMBL278330 | 0.86 | CDK1 (0.54) | CDK1CCNB1CA2CA9L3MBTL1 | |
| Sucrose SCHEMBL8367950 | 0.86 | CDK1 (0.71) | CDK1CCNB1CA2CA9L3MBTL1 | |
| Sucrose SCHEMBL19668079 | 0.86 | CDK1 (0.71) | CDK1CCNB1CA2CA9L3MBTL1 | |
| Sucrose SCHEMBL2961001 | 0.85 | CDK1 (0.78) | CDK1CCNB1CA2CA9L3MBTL1 | |
| Sucrose SCHEMBL24202550 | 0.85 | CDK1 (0.82) | CDK1CCNB1CA2CA9L3MBTL1 | |
| Sucrose SCHEMBL25403456 | 0.85 | CDK1 (0.82) | CDK1CCNB1CA2CA9L3MBTL1 | |
| Sucrose SCHEMBL24274201 | 0.85 | CDK1 (0.82) | CDK1CCNB1CA2CA9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846044-B2 | Stabilizing alkylglycoside compositions and methods thereof | AEGIS THERAPEUTICS, LLC (US) | 2014-09-30 | — | — | US | claimed |
| CN-118324870-A | Improved peptide drugs for insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4397374-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mederis Diabetes, LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-117903257-A | Improved peptide drugs for insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11911447-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES LLC (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117582516-A | Improved peptide drugs against insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-3155017-B1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117180445-A | Improved peptide drugs against insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4286400-A2 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-2709645-B1 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-2076281-A1 | STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF | Aegis Therapeutics, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080268032-A1 | For reducing aggregation or immunogenicity of peptide or polypeptide including an alkylglycoside, especially dodecyl maltoside, tridecyl maltoside, sucrose monododecanoate, sucrose monotridecanoate, or sucrose monotetradecanoate; treatment of obesity | AEGIS THERAPEUTICS LLC (US) | 2008-10-30 | — | — | US | disclosed |
| US-7425542-B2 | Stabilizing alkylglycoside compositions and methods thereof | AEGIS THERAPEUTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080194461-A1 | Stabilizing Alkylglycoside Compositions and Methods Thereof | AEGIS THERAPEUTICS LLC (US) | 2008-08-14 | — | — | US | disclosed |
| US-7390788-B2 | Pharmaceutically active peptide T composition comprising non-aggregated D-ala1-Peptide T-amide, produced by suspending the D-ala1-Peptide T-amide in 80% trifluoroethanol for 24 hours at 37 C with shaking, removing trifluoroethanol, and suspending the D-ala1-Peptide T-amide in aqueous solution | PEPTIDE ACCOUNT LLC | 2008-06-24 | — | — | US | disclosed |
| US-20070298010-A1 | Stabilizing alkylglycoside compositions and methods thereof | AEGIS THERAPEUTICS LLC (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007149096-A1 | STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF | AEGIS THERAPEUTICS, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070111938-A1 | Peptide pharmaceutical compositions | RAPID PHARMACEUTICALS, LLC (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007002465-A2 | STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF | RAPID PHARMACEUTICALS, LLC (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060045869-A1 | Absorption enhancers for drug administration | AEGIS THERAPEUTICS LLC | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911447-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, PTMS | CDK1 3499/4885CCNB1 4646/4885CA2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.